APA (7th ed.) Citation

Hu, S., Wu, Z., Dai, Y., Shi, X., Hu, Q., Liu, C., . . . Zhou, G. (2025). Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy. Cancer Biology & Medicine, 22(12), 1544. https://doi.org/10.20892/j.issn.2095-3941.2025.0393

Chicago Style (17th ed.) Citation

Hu, Shuyi, et al. "Immunotherapy Rechallenge of Patients with Advanced NSCLC Progression After Sequential Treatment with Third-generation EGFR-TKI and Immunotherapy." Cancer Biology & Medicine 22, no. 12 (2025): 1544. https://doi.org/10.20892/j.issn.2095-3941.2025.0393.

MLA (9th ed.) Citation

Hu, Shuyi, et al. "Immunotherapy Rechallenge of Patients with Advanced NSCLC Progression After Sequential Treatment with Third-generation EGFR-TKI and Immunotherapy." Cancer Biology & Medicine, vol. 22, no. 12, 2025, p. 1544, https://doi.org/10.20892/j.issn.2095-3941.2025.0393.